AIMS: We performed a head-to-head comparison of an antibody against uroplakin III (UP3) and a new uroplakin II (UP2) antibody that remains untested in diagnostically challenging settings. METHODS AND RESULTS: We immunostained high-grade bladder neck carcinomas (n = 35), high-grade upper tract urothelial carcinomas (UC) and renal carcinomas (n = 85), metastases of UC (n = 30) and a multicancer tissue microarray (n = 88) for UP3 and UP2, and scored staining intensity and proportion. UP3 showed membranous plaque-like expression, while UP2 staining showed both membranous and cytoplasmic positivity. Significantly greater intensity (P = 0.003) and proportion (P = 0.03) of staining was noted for UP2 among bladder neck lesions, with UP2 staining showing greater sensitivity (63% versus 19%) and similar specificity (95% versus 100%) for UC over prostate carcinoma (P = 0.02). Among upper tract lesions, UP2 staining showed greater intensity and proportion than UP3 (both P < 0.001), including improved sensitivity (68% versus 23%) and equal specificity (both 100%) for UC (P = 0.006). Among UC metastases, UP2 staining showed greater intensity and proportion (both P < 0.001) with higher sensitivity (73% versus 37%, respectively, P = 0.001). Of 88 additional cases tested, no non-urothelial cases stained for either UP. CONCLUSIONS: The UP2 antibody outperforms the UP3 antibody, including in diagnostically challenging settings, and is a useful addition to the armamentarium of biomarkers for UC.
AIMS: We performed a head-to-head comparison of an antibody against uroplakin III (UP3) and a new uroplakin II (UP2) antibody that remains untested in diagnostically challenging settings. METHODS AND RESULTS: We immunostained high-grade bladder neck carcinomas (n = 35), high-grade upper tract urothelial carcinomas (UC) and renal carcinomas (n = 85), metastases of UC (n = 30) and a multicancer tissue microarray (n = 88) for UP3 and UP2, and scored staining intensity and proportion. UP3 showed membranous plaque-like expression, while UP2 staining showed both membranous and cytoplasmic positivity. Significantly greater intensity (P = 0.003) and proportion (P = 0.03) of staining was noted for UP2 among bladder neck lesions, with UP2 staining showing greater sensitivity (63% versus 19%) and similar specificity (95% versus 100%) for UC over prostate carcinoma (P = 0.02). Among upper tract lesions, UP2 staining showed greater intensity and proportion than UP3 (both P < 0.001), including improved sensitivity (68% versus 23%) and equal specificity (both 100%) for UC (P = 0.006). Among UC metastases, UP2 staining showed greater intensity and proportion (both P < 0.001) with higher sensitivity (73% versus 37%, respectively, P = 0.001). Of 88 additional cases tested, no non-urothelial cases stained for either UP. CONCLUSIONS: The UP2 antibody outperforms the UP3 antibody, including in diagnostically challenging settings, and is a useful addition to the armamentarium of biomarkers for UC.
Authors: Mahul B Amin; Steven C Smith; Victor E Reuter; Jonathan I Epstein; David J Grignon; Donna E Hansel; Oscar Lin; Jesse K McKenney; Rodolfo Montironi; Gladell P Paner; Hikmat A Al-Ahmadie; Ferran Algaba; Syed Ali; Isabel Alvarado-Cabrero; Lukas Bubendorf; Liang Cheng; John C Cheville; Glen Kristiansen; Richard J Cote; Brett Delahunt; John N Eble; Elizabeth M Genega; Christian Gulmann; Arndt Hartmann; Cord Langner; Antonio Lopez-Beltran; Cristina Magi-Galluzzi; Jorda Merce; George J Netto; Esther Oliva; Priya Rao; Jae Y Ro; John R Srigley; Satish K Tickoo; Toyonori Tsuzuki; Saleem A Umar; Theo Van der Kwast; Robert H Young; Mark S Soloway Journal: Mod Pathol Date: 2014-11-21 Impact factor: 7.842
Authors: Ricardo L Favaretto; Stênio C Zequi; Renato A R Oliveira; Thiago Santana; Walter H Costa; Isabela W Cunha; Gustavo C Guimarães Journal: Int Braz J Urol Date: 2018 Jan-Feb Impact factor: 1.541